Overview

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Status:
Recruiting
Trial end date:
2024-01-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
Phase:
Phase 2
Details
Lead Sponsor:
Revolution Medicines, Inc.
Collaborators:
Amgen
Sanofi